Skip to content
Back to meeting Original
Manuel Dómine, MD, PhD· @ManuelDomine · X·· 1 day agoScore70
Body

KRaSCENDO Trial. Excellent results comparing Divarasib (anext generation KRAS inhibitor) with sotorasib showing a clear benefit in PFS, OS, with rapid and durable responses. @oncoalert @myesmo #ESMO2026 MADRID @Hospital_FJD @quironsalud #LCSM

29 views · 4 likes · 2 reposts · 0 replies

Conference abstracts

Source: Manuel Dómine, MD, PhD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.